Kronos Bio develops therapies that target dysregulated transcription factors within their transcriptional regulatory networks to treat hard-to-reach cancers and autoimmune diseases. Their pipeline includes molecules like Istisociclib, a CDK9 inhibitor for MYC-dependent tumors, and KB-9558, which targets the KAT domain of p300 in multiple myeloma and HPV-driven tumors.
Funding
$155M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
PAFounders
Product
Problem
Many cancers and autoimmune diseases are driven by dysregulated transcription factors, which have historically been difficult to target with traditional drug development approaches. Targeting these transcription factors in isolation has proven largely unsuccessful.
Solution
Kronos Bio develops therapeutics that target dysregulated transcription factors within their transcriptional regulatory networks (TRNs) to treat cancers and autoimmune diseases. Instead of targeting transcription factors in isolation, Kronos Bio analyzes the entire TRN to identify critical nodes responsible for a transcription factor’s activity, providing multiple avenues for therapeutic intervention. Their pipeline includes molecules targeting key nodes within these networks, such as CDK9 and the KAT domain of p300.
Target Audience
The primary target audience includes patients with cancers and autoimmune diseases driven by dysregulated transcription factors, as well as pharmaceutical companies seeking novel therapeutic targets.
Features
- Focus on transcriptional regulatory networks (TRNs) rather than individual transcription factors
- Istisociclib (KB-0742): A CDK9 inhibitor being evaluated for MYC-dependent tumors
- KB-9558: Targets the KAT domain of p300, a critical node of the IRF4 TRN, for multiple myeloma and HPV-driven tumors
- KB-7898: A p300 KAT inhibitor being developed for the potential treatment of Sjögren’s disease
- Discovery collaboration with Genentech to advance novel therapies against transcriptional targets in oncology